Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In addition to meeting guidance for NEXICART-2 enrollment completion and announcing topline NEXICART-2 results expected Q3 2026, Immix has onboarded chief medical officer, Richard Graydon. Graydon is a board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck (MRK).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma price target raised to $15 from $14 at Mizuho
- Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
- Immix Biopharma Amends ATM Offering to Raise Capital
- Immix Biopharma initiated with an Overweight at Morgan Stanley
- Immix Biopharma initiated with an Outperform at Citizens